These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 29808010)

  • 1. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
    Wong GS; Zhou J; Liu JB; Wu Z; Xu X; Li T; Xu D; Schumacher SE; Puschhof J; McFarland J; Zou C; Dulak A; Henderson L; Xu P; O'Day E; Rendak R; Liao WL; Cecchi F; Hembrough T; Schwartz S; Szeto C; Rustgi AK; Wong KK; Diehl JA; Jensen K; Graziano F; Ruzzo A; Fereshetian S; Mertins P; Carr SA; Beroukhim R; Nakamura K; Oki E; Watanabe M; Baba H; Imamura Y; Catenacci D; Bass AJ
    Nat Med; 2018 Jul; 24(7):968-977. PubMed ID: 29808010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.
    Zheng W; Yang Z; Song P; Sun Y; Liu P; Yue L; Lv K; Wang X; Shen Y; Si J; Zhang X; Ke Y; Cheng H; Hu W
    Cancer Lett; 2023 Feb; 555():216029. PubMed ID: 36493900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.
    Yamasaki J; Hirata Y; Otsuki Y; Suina K; Saito Y; Masuda K; Okazaki S; Ishimoto T; Saya H; Nagano O
    Cancer Sci; 2022 Mar; 113(3):916-925. PubMed ID: 34931404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
    Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing SHP2-based combination therapy for KRAS-amplified cancer.
    Li T; Kikuchi O; Zhou J; Wang Y; Pokharel B; Bastl K; Gokhale P; Knott A; Zhang Y; Doench JG; Ho ZV; Catenacci DV; Bass AJ
    JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 17. A combinatorial strategy for treating KRAS-mutant lung cancer.
    Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
    Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 20. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.